Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31264688.
- Also identified by DOI 10.1093/infdis/jiz164 and PMC identifier 6603965.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This commentary considers an extreme idea for protecting against human immunodeficiency virus (HIV) transmission to sex partners of individuals participating in HIV remission studies with an analytical treatment interruption (ATI). Other human challenge studies, such as studies of influenza, commonly isolate participants during the trial, to protect their contacts and the community against infection. Why should HIV studies with a treatment interruption be any different, one might wonder? This article concludes that isolation should not be used in HIV remission studies with an ATI but also shows that the matter is complex.
Medical subject headings
- Anti-HIV Agents
- Coinfection
- HIV Infections
- Patient Isolation
- Vaccines
- Withholding Treatment